EBS Emergent BioSolutions Inc.

Emergent BioSolutions Appoints Nina DeLorenzo as Senior Vice President of Global Public Affairs

Emergent BioSolutions Appoints Nina DeLorenzo as Senior Vice President of Global Public Affairs

GAITHERSBURG, Md., April 06, 2020 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) today announced the appointment of Nina DeLorenzo to the position of senior vice president for global public affairs. DeLorenzo will oversee external relations, corporate communications, advocacy, and corporate social responsibility. She will be responsible for developing and leading the company’s global public affairs strategy and providing strategic communications counsel to the executive management team.

Robert G. Kramer Sr., president and chief executive officer at Emergent BioSolutions, stated, “On behalf of the management team, I am pleased to welcome Nina to Emergent. Her deep bench of public affairs and public policy experience uniquely qualify her for this critical role, and we look forward to both her leadership and strategic counsel during a pivotal time for our company. As we continue in pursuit of our vision to protect or enhance 1 billion lives by 2030, I am confident that her wide range of expertise will strengthen our position as a trusted leader in the public health space.”

“I am thrilled to join the Emergent team, especially at this critical time, where our mission—to protect and enhance life—is front and center in the fight against COVID-19,” said DeLorenzo. “Emergent’s longstanding track record of success, enabling the U.S. government and others to address our nation’s public health threats provides a real and very relevant opportunity to strengthen its public footprint, and I am proud to join this important effort.”

DeLorenzo has 25 years of experience in public affairs, government affairs, and communications in the public and private sectors. She most recently served as chief of staff, external affairs at Sanofi in Paris, France. Her prior experience includes government affairs, communications, and public policy roles at AbbVie, Pfizer Inc, Schering-Plough Corp. (now Merck), and at the Pharmaceutical Research and Manufacturers of America (PhRMA). DeLorenzo served in the administration of President George W. Bush at the White House Coalition Information Center and at the U.S. Department of State. Prior to this, she held roles in government and on political campaigns.

About Emergent BioSolutions

Emergent BioSolutions is a global life sciences company whose mission is to protect and enhance life. Through our specialty products and contract development and manufacturing services, we are dedicated to providing solutions that address public health threats. Through social responsibility, we aim to build healthier and safer communities. We aspire to deliver peace of mind to our patients and customers so they can focus on what’s most important in their lives. In working together, we envision protecting or enhancing 1 billion lives by 2030. For more information visit . Find us on LinkedIn and follow us on Twitter @emergentbiosolu and Instagram @life_at_emergent.

Investor Contact:

Robert G. Burrows

Vice President, Investor Relations

240-631-3280

Media Contact:

Lynn Kieffer

Vice President, Corporate Communications

240-631-3391

EN
06/04/2020

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Emergent BioSolutions Inc.

 PRESS RELEASE

Emergent BioSolutions Reports Second Quarter 2025 Financial Results

Emergent BioSolutions Reports Second Quarter 2025 Financial Results Second Quarter 2025 Total Revenues of $140.9 million, above Q2 guidance by $21 millionSecond Quarter 2025 Net Loss of $12.0 million and Net Loss Margin of (9)%, an improvement of 96% and 10,200 bps, respectively, versus prior yearSecond Quarter 2025 Gross Margin % of 36% and Adjusted Gross Margin % of 49%, an expansion of 6,200 bps and 2,300 bps, respectively, versus prior yearSecond Quarter 2025 Adjusted EBITDA of $28.5 million, an increase of 382% versus prior yearSecond Quarter 2025 Adjusted EBITDA Margin of 20% of Total...

 PRESS RELEASE

New Publication in Expert Review of Anti-infective Therapy Evaluates B...

New Publication in Expert Review of Anti-infective Therapy Evaluates Brincidofovir as Potential Antiviral Treatment for Mpox Ongoing mpox outbreak continues to be a global health threat and is driving need for greater therapeutic research and innovation GAITHERSBURG, Md., July 28, 2025 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) today announced the publication of a comprehensive review article, "Brincidofovir in the Era of Mpox," in the peer-reviewed journal Expert Review of Anti-infective Therapy.1 This publication includes an overview of brincidofovir, in vitro and in v...

 PRESS RELEASE

Emergent Applauds Availability of Over-the-Counter Naloxone in U.S. Ho...

Emergent Applauds Availability of Over-the-Counter Naloxone in U.S. House of Representatives GAITHERSBURG, Md., July 28, 2025 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) today announces its recognition of the U.S. House of Representatives for adding over-the-counter (OTC) naloxone to every AED location in its buildings, providing direct access to first responders and anyone coming across an individual who may be experiencing an opioid overdose. This effort has been led by Representative Buddy Carter (R-GA), with his team and congressional constituents, who have kept this pu...

 PRESS RELEASE

Emergent BioSolutions to Report Second Quarter 2025 Financial Results ...

Emergent BioSolutions to Report Second Quarter 2025 Financial Results on August 6, 2025 GAITHERSBURG, Md., July 15, 2025 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) will host a conference call on Wednesday, August 6, 2025, at 5:00 pm eastern time to discuss the financial results for the second quarter of 2025. Participants can access the conference call live via and also by visiting the page of Emergent’s website. To participate via telephone, please register in advance at this . Upon registration, all telephone participants will receive a confirmation email detailing ho...

 PRESS RELEASE

Emergent BioSolutions Secures $51.9 Million Contract Modification Awar...

Emergent BioSolutions Secures $51.9 Million Contract Modification Award for CNJ-016® [Vaccinia Immune Globulin Intravenous (Human)] (VIGIV) as part of U.S. Biodefense Preparedness Efforts GAITHERSBURG, Md., July 08, 2025 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) today announced a contract modification has been secured to deliver CNJ-016® [Vaccinia Immune Globulin Intravenous (Human)] (VIGIV) to the Administration for Strategic Preparedness and Response (ASPR), part of the U. S. Department of Health and Human Services (HHS), for smallpox preparedness. ASPR exercised an opt...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch